Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
The Summit will also witness participation of Union Minister of Health & Family Welfare and Chemicals & Fertilizers Dr. Mansukh Mandaviya
Two out of three people under the age of 40 are at risk of prediabetes
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The 50,000 square foot expansion will house a high-speed filling line and lyophilizers, which will increase the facility’s sterile injectable capacity by 50%
Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021
Natco Pharma has reported consolidated financial results for the period ended September 30, 2021
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.
Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021
The consideration for the acquisition is US $ 2.25 million
Evidence also shows better immune response to virus among users of spray
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Subscribe To Our Newsletter & Stay Updated
